HUTCHMED (China) (HCM) H2 2025 earnings summary

Executive summary

• Achieved $366.2 million in ex-China FRUZAQLA sales, up 26% year-over-year, with rollout to 38+ countries and a rebound in China sales in H2 2025.

• Maintained a robust cash position of $1.4 billion, driven by the SHPL divestment, supporting accelerated R&D and business development.

• Net income reached $457.7 million, primarily due to a one-time SHPL divestment gain; core operations remain profitable excluding this.

• Advanced next-generation innovation with multiple NDA filings, approvals, and global expansion of the ATTC platform.

• Multiple NDA filings and regulatory milestones expected in 2026, including SAFFRON and SANOVO readouts.

Financial highlights

• Oncology/Immunology consolidated revenue was $285.5 million, including $71 million from R&D-related upfront and milestone payments.

• R&D expenses decreased to $148.3 million from $212.1 million in 2024, reflecting a transition from late-stage trials to next-wave ATTCs.

• Cash and short-term investments increased to $1.37 billion from $836 million year-over-year.

• Operating expenses decreased to $587.7 million from $673.9 million in 2024.

• Oncology revenue guidance for 2026 is $330 million–$450 million, reflecting anticipated growth from new indications and global expansion.

Outlook and guidance

• 2026 oncology revenue guidance set at $330 million–$450 million, driven by China commercial growth and FRUZAQLA expansion.

• R&D investment expected to ramp up to $250 million–$300 million in coming years, balanced by commercial income.

• Multiple NDA approvals and clinical milestones anticipated within 15 months, including for savolitinib, fruquintinib, and surufatinib.